Project Description
Nexvet, a biologic therapeutics company developing a pipeline of monoclonal antibody (mAb) therapies for companion animals in pain and other therapeutic areas. Nexvet was acquired by Zoetis (NYSE:ZTS) in July 2017.
Nexvet2018-07-31T16:12:16+00:00